Active Biotech (ACTI.ST)

Executive Summary

Active Biotech is a Swedish biopharmaceutical company developing novel immunomodulatory therapies for cancer and inflammatory eye diseases. Founded in 1983 and headquartered in Lund, the company leverages both small, orally active molecules and antibody-based immunotherapies to modulate the immune system. Its pipeline is pre-clinical, focusing on innovative approaches to address unmet medical needs in oncology and ophthalmology. The company is publicly traded on the Stockholm Stock Exchange under the ticker ACTI.ST, with a current valuation of approximately $148 million. The company's lead candidates are in pre-clinical development, targeting immune checkpoint modulation and tumor microenvironment reprogramming. Key near-term catalysts include the initiation of a first-in-human Phase 1 trial for its lead oncology asset, which could validate its oral immunotherapy platform. Additionally, Active Biotech is expected to present pre-clinical data at major medical conferences, potentially attracting partnership interest. While the early-stage nature of the pipeline carries inherent risk, the modular technology platform and clear mechanism of action provide a differentiated approach. Successful clinical translation could unlock significant value, but investors should monitor regulatory and enrollment timelines closely.

Upcoming Catalysts (preview)

• H2 2026Phase 1 trial initiation for lead oncology candidate70% success
• Q3 2026Preclinical data presentation at ESMO or similar conference90% success
• TBDPotential partnership or licensing deal for ophthalmology asset30% success